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Abstract 
Sustained vaginal delivery of siRNA has been precluded by the mucosal barrier lining the vaginal 
tract.  In contrast to prior reports, we showed that conventional lipoplexes administered 
intravaginally are unable to reach vaginal epithelium under normal physiological conditions.  Here 
we have developed a novel alginate scaffold system containing muco-inert PEGylated lipoplexes to 
provide a sustained vaginal presence of lipoplexes in vivo and to facilitate the delivery of 
siRNA/oligonucleotides into the vaginal epithelium.  These PEGylated lipoplex-entrapped alginate 
scaffolds (PLAS) were fabricated using a freeze-drying method and the entrapment efficiency, 
release rate, and efficacy were characterized.  We demonstrated that these PLAS system had an 
entrapment efficiency of ~50%, which released PEGylated lipoplexes gradually both in vitro and in 
vivo.  While the presence of alginate diminished the cell uptake efficiency of PEGylated lipoplexes 
in vitro, as expected, we showed a six-fold increase their uptake into the vaginal epithelium 
compared to existing transfection systems following intravaginal administration in mice.  A 
significant knockdown of Lamin A/C level was also observed in vaginal tissues using siLamin A/C-
containing PLAS system in vivo.  Overall, our results indicated the potential of the biodegradable 
PLAS system for the sustained delivery of siRNA/oligonucleotides to vaginal epithelium. 
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1. Introduction 
Vaginal application of nucleic acids holds great potential for the prevention and treatment of 
various viral infections responsible for diseases such as genital herpes, acquired immune deficiency 
syndrome (AIDS) and cervical cancer (Reviewed in [1]).  Vaginal administration is non-invasive, 
bypasses first pass hepatic clearance and provides local delivery to the target tissue and has been 
described in several pre-clinical trials using plasmid DNA for vaccination [2] or small interfering 
RNA (siRNA) for prevention of herpes simplex virus (HSV) infections [3].  For DNA vaccination, 
plasmid DNA needs to be delivered to the immune cells in the mucus to induce the desired immune 
response [4].   In contrast, vaginal treatment of cancer or viral infections by gene silencing is more 
challenging as it requires the siRNA molecules to be delivered through the mucosal barrier, avoid 
rapid nuclease degradation, and be taken up by the cervicovaginal epithelium. 
 
Mucus presents as a one of the biggest hurdles for efficient vaginal siRNA delivery.  It serves as a 
protective barrier for underlying tissues and removes foreign particles efficiently [5].   Thus, 
sustained release at the mucosal site, though desirable, is challenging.  In addition, the changes in 
the physical environment in the vaginal cavity throughout the estrous cycle could also dramatically 
affect the delivery efficiency [2].  To overcome these barriers, strategies such as the use of 
progesterone or mucus removal in the vaginal cavity prior to siRNA administration have been 
examined with success in the past by using liquid-based formulations such as cationic transfection 
reagents [3], cholesterol-conjugated siRNA [6], or biodegradable poly(lactic-co-glycolic acid) 
(PLGA) nanoparticles [7].  However, a solid vaginal siRNA delivery system which can be retained 
in the vaginal cavity following administration without prolonged anaesthesia is yet to be developed.  
Such a system could significantly improve clinical outcome.  Thus, in this present study, we aimed 
to develop a more clinically applicable vaginal siRNA delivery platform which cannot only be 
retained in the vaginal cavity following administration but also delivers siRNA efficiently to 
vaginal tissues under normal physiological conditions. 
 
In this report, we described a novel PEGylated Lipoplex-entrapped Alginate Scaffold (PLAS) 
system which brings together a muco-inert non-viral gene delivery vector, to avoid trapping and 
clearance by the mucus barrier, and a biodegradable alginate tissue-engineered scaffold which 
provides continuous presence of the siRNA in the vaginal cavity.  Alginate is a naturally–occurring 
polysaccharide which is readily cross-linked by the use of divalent cations such as calcium, into a 
solid matrix without the use of organic solvents [8, 9].  Alginate scaffolds decompose in the 
presence of sodium ions, naturally occurring in the body, and can thus release entrapped 
therapeutics slowly over time [10].  While its use in gene delivery has been demonstrated in the 
forms of microspheres [8], poly-ionic complexes [11-13] or hydrogel [9], here we investigated for 
the first time the feasibility of entrapping PEGylated lipoplexes within a solid alginate scaffold 
system and examined its potential for sustained delivery of nucleic acids to the female reproductive 
tract.  We investigated the entrapment efficiency, release kinetics of lipoplexes at different 
formulation conditions, as well as the efficiency of the released lipoplexes to be taken up by cells 
both in vitro and in vivo.  To our knowledge, this is the first report which describes the use of 
biodegradable matrices for vaginal delivery of nucleic acids. 
 
2. Materials and Methods 
2.1. Materials 
Dioleoyl trimethylammonium propane (DOTAP) and cholesterol were purchased from Sigma (St 
Louis, MO) and dioleoyl phosphatidylethanolamine (DOPE) was obtained from Northern Lipids 
(Vancouver, Canada).  Polyethylene Glycol (PEG)2000-C16Ceramide conjugate was from Avanti 
Polar Lipids (Alabaster, AL).  Sodium alginate was purchased from Concept Biotech Inc (CBI, 
Taichung, Taiwan).   
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Oligonucleotides (5’-GTCAGAAATAGAAACTGGTCATC-3’; 5’-
GATGACCAGTTTCTATTTCTGAC-3’) with or without fluorescein isothiocyanate (FITC) 
labeling were obtained from Invitrogen (Carlbad, CA).   Green fluorescent protein (GFP) targeted 
siRNA with sense sequence of 5’-GCACGACUUCUUCAAGUCCUU-3’was purchased from 
Sigma-Aldrich (St Louis, MO) in annealed form.  Lamin A/C targeted siRNA with sense sequence 
of 5’CUGGACUUCCAGAAGAACAdTdT-3’ and non-targeting siRNA with sense sequence of 5’- 
UUAUGCCGAUCGCGUCACAUU-3’ were obtained from GenePharma (Shanghai, China). 
 
HeLa cells were obtained from the American Type Culture Collection (Manassas, VA) and GFP-
expressing HeLa cells were prepared according to protocols described in Gu et al [14].  All cells 
were maintained in 0.2% primocin (Invivogen, San Diego, CA) containing Dulbecco’s Modified 
Eagle Medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% heatinactivated fetal 
bovine serum (FBS; Bovogen, Keilor East, Australia) and 2mM L-glutamine (Invitrogen). 
 
All other chemicals and solvents used were analytical grade. 
 
2.2. Liposome Formulations 
Non-PEGylated liposomes were prepared using a thin film hydration method as described 
previously [15].  Briefly, a dried lipid thin film consisting of DOTAP, cholesterol and DOPE 
(1:0.5:0.5 molar ratio) was hydrated with sterile 5% dextrose solution to give a final total lipid 
concentration of 5 mM.  Following stabilization at room temperature for two hrs, liposomes were 
extruded through a series of NucleoporeTM track-etched membranes using a LipexTM extruder 
(Northern lipids) under nitrogen pressure.  The resulting small unilamellar liposomes (<100 nm) 
were subsequently complexed with oligonucleotides at an Nitrogen:Phosphate (N:P) ratio of 4.   
 
PEGylated liposomes were prepared using the hydration of freeze-dried matrix (HFDM) method as 
described previously [16].  DOTAP, cholesterol, DOPE and PEG2000C16Cermide with a molar ratio 
of 50:35:5:10 was used.  The final freeze dried matrix was hydrated with sterile water and the final 
mixture contained 40 μg of oligonucleotides in 300 μL of isotonic sucrose solution. 
 
2.3. Preparation of PEGylated Lipoplex-entrapped Alginate Scaffold (PLAS) 
Systems 
2.3.1. Fabrication of Alginate Scaffolds, Characterisation, and Surface Morphology 
Two different procedures were used to fabricate the alginate scaffolds: freeze-dried and air-dried 
methods.  For the freeze dried method, 2% alginate (Concept Biotech Inc) solution was prepared 
using sterile isotonic dextrose solution.  The mixture was then pipetted into plastic molds (2.2 cm x 
2cm in size) and gradually frozen to around -80°C and subsequently dried in a lyophilizer (ALPHA 
1–2 LDplus, Martin Christ, Germany) overnight.  The dried matrix was subsequently cross-linked 
with calcium using 5% CaCl2 solution and was then left at room temperature overnight.  For the air-
dried method, the frozen alginate block was immersed in 5% CaCl2 solution without being 
lyophilised until the scaffold structure was formed completely.  The scaffold system was then 
allowed air-dried overnight at room temperature.  The dimensions of the scaffolds were measured 
before and after wetting with water.  To examine the surface morphology, the scaffolds were 
attached to aluminium stubs using carbon tabs.  The scaffolds were subsequently sputter coated 
with platinum using a Metaserv automatic mounting press and micrographs of the scaffolds were 
obtained using a Scanning electron microscope (SEM, JEOL JSM-7001F) at a voltage of 10 kV. 
2.3.2. Entrapment Efficiency of PEGylated Lipoplexes within the Scaffold System 
PEGylated lipoplexes were entrapped into the alginate scaffold system at alginate:lipid (A:L) ratios 
of 5:1 to 10:1 (w/w).  Briefly, PEGylated lipoplexes, containing 20 to 80 μg oligonucleotides, were 
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gently mixed with the alginate solution by pipette and the resulting mixtures was added to 5 mL 
tubes and were slowly frozen.  The scaffold system was then fabricated using the freeze-dried 
method described above.  The entrapment efficiency of the PEGylated lipoplexes within the 
scaffold system was calculated by subtracting the amount of oligonucleotides lost in the CaCl2 
solution during the cross-linking step from the initial amount of oligonucleotides added in the 
formulation.  The concentration of oligonucleotides in the CaCl2 solution was determined using 
Quant-iT™ PicoGreenTM reagent (Invitrogen) following removal of the alginate scaffold.  Briefly, 
the samples were diluted in 5% CaCl2 solution to a concentration within the linear range of the 
standard curve (1-1,000 ng/mL, in CaCl2 solution).  Samples were then treated with 0.5% Triton-X 
100 (Sigma), which destabilized the lipoplexes to release entrapped oligonucleotides.  One hundred 
μL of diluted PicoGreen reagent (1:200 dilution) was then added to 100 μL samples in a 96-well 
plate according to the manufacturer’s instruction.  Fluorescence intensity was subsequently 
measured using a FluostarTM plate reader at 485 nm excitation and 520 nm emission wavelengths.  
Sample concentrations were subsequently calculated using the standard curve.  Three batches of 
samples were tested for each formulation condition (n=3) and the assay was performed in 
duplicates. 
2.3.3. Particle characterisation 
Particle size of the PEGylated lipoplexes was determined following lyophilisation in the presence of 
alginate.  Formulations with alginate:lipid ratios of 6 and 8 were examined.  Following hydration of 
the freeze-dried alginate scaffolds, the samples were centrifuged at 5000g for 10 mins to remove 
still-yet-to-be degraded alginate scaffold and the percentage of siRNA remaining in the supernatant 
was determined using PicogreenTM assay as described above.  The size of the released lipoplexes 
was subsequently measured using Zetasizer Nano ZSTM (Malvern Instruments, Malvern, UK) as 
previously described [16].  Three or four batches of samples were examined for each formulation 
(n=3 or 4). 
  
2.3.4. Release Kinetics 
To determine the release rate of lipoplexes from the cross-linked alginate scaffold, formulations 
containing 10-15 μg of oligonucleotides were immersed in 5 mL of phosphate buffered saline (PBS) 
or citrate buffer (150 mM, pH 5.0).  Citrate buffer was prepared at a sodium concentration of 6 g/L.  
The lipoplex scaffolds were prepared at alginate:lipid ratios ranging from 5:1 to 30:1.  Samples 
were incubated at 37oC with gentle shaking (70 rpm) and the release of lipoplexes was monitored 
over time.  At each time point, 250 µL of the samples was collected and the volume was replaced 
with fresh buffer for continued monitoring of the release.   The concentration of the released 
oligonucleotides was determined using the PicogreenTM assay kit as described above.  Standard 
curves (1 -1,000 ng/mL) were generated in citrate buffer and PBS.  Three batches of alginate 
scaffold were prepared for each experiment and all assays were performed in triplicate. 
 
2.3.5. In vitro Efficacy  
To examine the influence of alginate on the uptake efficiency of PEGylated lipoplexes into cells or 
the gene silencing efficiency of siRNA, FITC-labeled oligonucleotides or GFP-targeted siRNA 
were incorporated into the PEGylated liposomes.  The PEGylated lipoplex-entrapped alginate 
scaffold (PLAS) systems were prepared at alginate:lipid ratios ranging from 5:1 to 10:1.  HeLa or 
GFP-expressing HeLa cells were seeded in 6-well plates 24 hrs prior to transfection at a density of 
100,000 cells/well.  The scaffold system containing 20 μg of FITC-oligonucleotides or GFP-
targeted siRNA was hydrated with 1.5 mL PBS and the samples were then allowed to stabilize at 
room temperature for 2 hrs prior to addition to cells.  Cells were incubated with 2 mL of media 
containing 2.6 μg of FITC-oligonucleotides/GFP siRNA overnight for cell uptake or 48 hrs for gene 
knockdown.  PEGylated lipoplexes and alginate-only samples which contained the highest amount 
of alginate used in the experiment were both included in the experiment as a positive and a negative 
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control, respectively.  OligofectamineTM was also used according to the manufacturer’s instructions.  
Final oligonucleotide/siRNA concentration for all formulations was 100nM.  At the termination of 
the experiment, cells were trypsinised and resuspended in 2% paraformaldehyde (Sigma-Aldrich) in 
PBS.  Samples were kept at 4°C in the dark before the fluorescence intensities of cells being 
quantified by BD-FACSCantoTM flow cytometry.  All formulations were tested in triplicate (n=3). 
 
2.4. Animals, Nucleic Acid Preparation/Administration, and Efficacy 
Assessment in vivo 
K14E7 (10 week-old) and C57BL/6 (8 week-old) female mice were obtained from ARC (Perth, 
Australia).  All experiments were approved by the University of Queensland Animal Ethics 
Committee.  All uptake and siRNA delivery efficiency experiments were performed using C57BL/6 
mice while paraffin sections from the vaginal tissues of K14E7 mice were used to assess the 
changes in the physical environment in the vaginal cavity during mice estrous cycle.   
 
All formulations were administered intravaginally into PenthroxTM (Medical Developments 
International, Victoria, Australia) or ketamine (Parnell laboratories, New South Wales, Australia) 
and xylazil (Troy laboratories, New South Wales, Australia) anaesthetized mice with or without 
citric acid (5%) or nonoxynol-9 (N-9, ConceptrolTM, Ortho Options) pre-treatment using a GilsonTM 
p20 pipette.  Citric acid pre-treatment was performed similar to the procedure described previously 
[2].  Briefly, a cotton ball soaked with 5% citric acid aqueous solution was inserted into the vaginal 
tract for 2 hrs prior to nucleic acids treatment.  ConceptrolTM gel which contains 4% N-9 was 
applied to the vaginal cavity 6 hrs prior to lipoplexes administration [17].  VaselineTM was also 
applied at the vaginal introitus to prevent leakage for liquid-based formulations.  For alginate 
scaffold system, freeze-dried scaffolds with or without PEGylated lipoplexes were administered 
intravaginally into mice using a pair of forceps.  Eight µL of sterile saline was subsequently 
instilled into the vaginal cavity to help moisturising the scaffold.  For all experiments, two to three 
mice were used per treatment group. 
 
For the uptake study, FITC-labeled oligonucleotides (500-4,000 pmol) were incorporated into 
various lipid-based formulations including LipofectamineTM, cationic DOTAP liposomes, or 
PEGylated lipoplex-entrapped cross-linked alginate scaffold system.  All formulations were 
prepared according to manufacturer instructions or as described earlier.  For preparation of alginate 
scaffold system, alginate:lipid ratio of 8:1 was used and 2,000 pmol of FITC-Oligo was 
incorporated into the system.  LipofectamineTM (2 µL, Invitrogen) was used to complex with 500-
4,000 pmol of FITC-Oligo, as previously described [18].  For DOTAP liposomal formulations 
(contained 500-4,000 pmol of FITC-Oligo), complexes were formed in a concentration not to 
exceed 80 µg/mL before being concentrated to 12 µL using a 30K Ultra-free centrifugation filter 
(Millipore, New South Wales, Australia) immediately prior to administration into mice.  At 24 hrs 
post-administration, cervical and vaginal tissues were dissected and were immersed in Tissue-Tek 
O.C.T. Compound (ProSciTech, Queensland, Australia).  The tissues were then snap-frozen in an 
ethanol/dry ice bath.  Frozen sections (8 µm) were cut using a Leica CM 1850 cryostat (Leica 
Microsystems, Wetzlar, Germany) and were mounted on slides.  Sections were subsequently stained 
with propidium iodide (PI, 3.3 µg/mL) in VectashieldTM for co-localisation of FITC-
oligonucleotides before viewing using a Zeiss Axioskop 2 Plus fluorescence microscope.  
Percentages of co-localisation (% Area) were calculated in 5 randomly selected areas for various 
treatment groups using ImageJTM. 
 
For target-gene knockdown experiment, Lamin A/C targeted siRNA was used.  Each mouse 
received approximately 600pmole (8µg) of siRNA formulated in the PLAS system (alginate:lipid 
ratio of 8:1) per dose.  Two doses were administered intravaginally for each mouse on two 
consecutive days and the mice were sacrificed 24 hrs following the last treatment.  Three mice were 
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used in each treatment group (n=3).  Proteins were subsequently extracted from vaginal tissues and 
Lamin A/C levels were assessed for each specimen via western blotting using LaminA/C antibodies 
(1:1000, Cell Signaling Technology, Danvers, MA, USA).  β-tubulin (1:1000, Sigma) was used as a 
loading control.  Lamin A/C levels were quantified using ImageJ. 
 
2.5. Paraffin-embedded tissue sections 
Haematoxylin and eosin staining of the paraffin-embedded tissue sections from K14E7 mice was 
performed by the University of Queensland histological service.  
 
2.6. Statistical Analysis 
Data are presented as mean or mean ± standard error of the mean (SEM).  An unpaired Student’s t-
test (two-tailed, p<0.05) was used to determine statistically significant differences. 
 
3. Results 
3.1. Conventional liposomes fail to deliver nucleic acids into vaginal tissues 
We first sought to evaluate several commonly used transfection agents, LipofectamineTM, 
OligofectamineTM, or DOTAP-containing liposomes, for their effectiveness in delivering 
oligonucleotides into the vaginal tissues using previously described techniques [3, 18].  To 
determine uptake into vaginal tissues, we used 23 bp DNA oligonucleotides, fluorescently tagged 
with FITC, as a model molecule for siRNA.  As physical changes in the vaginal cavity throughout 
the estrous cycle can significantly affect the delivery of bioactives into vaginal tissues [2, 19], we 
first investigated its impact on lipoplexes.  Mice were monitored for their estrous cycle via daily 
examination of the outer vaginal tissues, with red and swollen tissues indicating estrous or 
proestrous.  Consistent with previous findings [2, 19], changes in mouse vaginal anatomy were 
observed at different phases of the cycle, with the outer layer of the epithelial cells becoming 
cornified and hyperkeratotic when mice were in estrous (Fig. 1).  To examine the effect of the 
cornified layer on the delivery of lipoplexes, DOTAP liposome-complexed FITC-labelled 
oligonucleotides (500-4,000 pmol) were administered intravaginally when mice were in estrous.  
Cervicovaginal tissues were dissected 24 hrs post-treatment and frozen sections were stained using 
propidium iodine to identify vaginal epithelium.  Lipoplexes administered at this stage of the 
estrous cycle resulted in strong uptake by cell debris present in the vaginal tract, however, no 
delivery was detected in the cervicovaginal epithelium (Fig. 2A).  Similarly, LipofectamineTM or 
OligofecatamineTM were unable to deliver oligonucleotides into the vaginal epithelium of mice in 
estrous, even at higher dosages (up to 4,000 pmol, data not shown).  We next sought to determine 
the oligonucleotide delivery efficiency in non-estrous mice using the same vectors.  
Disappointingly, despite extended sedation of mice (1 hr) to prevent leakage of the administered 
complexes, no uptake of the complexes into vaginal tissues at 24 hrs post-treatment was observed 
(Fig. 2B).  This was observed irrespective of the dose of lipoplexes administered (500-4,000 pmol 
FITC-oligonucleotides) or the delivery vectors used, LipofectamineTM (Fig. 2B) or DOTAP 
liposomes (data not shown). 
 
 
Figure 1 Hematoxylin and eosin staining of mouse 
cervicovaginal section in estrous.  Outer layer of the 
epithelial cells become cornified (arrows) when mice enter 
into estrous which creates a physical barrier for the effective 
delivery of bioactives into the epithelium.  The scale bar 
represents 200 µm. [Colour in print]. 
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3.2. Citric acid pre-treatment of the vaginal cavity improves the delivery of 
liposome-complexed oligonucleotides 
To enhance the delivery efficiency, we sought to pre-treat the vaginal cavity to improve its 
receptiveness to the delivery vectors.  Pre-treatment of the vaginal cavity with nonoxynol-9 (N-9) 
for 6 hrs has been shown to increase susceptibility to infection of human papilloma virus (HPV) due 
to disruption of the stratified genital epithelium [17].  However, we found that pre-treatment with 
N-9 did not result in an improvement in the delivery efficiency of lipoplexes to vaginal tissues (data 
not shown).  In contrast to N-9, pre-treatment with 5% citric acid for 2 hrs resulted in the delivery 
of lipoplexes into vaginal tissues, as shown by the presence of FITC-oligonucleotides within the 
vaginal tissue (counterstained with PI, Fig. 3).  The improved delivery may be a result of the citric 
acid inducing a transient and reversible opening of the tight junction in the vaginal epithelium [19].  
However, in contrast to the study reported by Kanazawa and colleagues, where a significant uptake 
of naked plasmid DNA was achieved following electroporation in citric acid pre-treated mice [2], 
we demonstrated that the delivery of oligonucleotides using conventional DOTAP-containing 
liposomes was still minimal under this treatment condition suggesting that these liposomes may not 
be able to mediate a clinically significant siRNA-derived therapeutic response intravaginally.   
3.3. Development of PEGylated lipoplex-entrapped alginate scaffold (PLAS) 
system 
The inefficient delivery of lipoplexes in the vaginal tissues was likely due to (1) the lack of 
retention of the lipoplexes in the vaginal cavity following administration and/or (2) inefficient 
transport of these lipoplexes through the mucus layer lining the cervicovaginal epithelium even 
following citric acid treatment.  Mucus is primarily composed of mucins, which can interact 
extensively with cationic liposomes [20] through its heavily glycosylated regions [21].  PEGylation 
has recently been reported to enhance particle stability in the presence of mucin [22] and 
Figure 2 Intravaginal delivery of 
lipoplexes.  (A) No delivery of FITC-
Oligonucleotides to the vaginal tissues 
was observed when DOTAP 
liposome-oligonucleotides complexes 
(500 pmol) were administered in 
estrous/proestrous state of the mouse 
estrous cycle.  In contrast, these 
complexes were taken up efficiently 
by cell debris present in the vaginal 
tract.  (B) No delivery of 
LipofectamineTM-complexed FITC-
oligonucleotides (500 pmol) into 
vaginal tissues was observed even 
when the administration was 
performed when mice were not in 
estrous.  All images were obtained at 
twenty-four hrs post-treatment and 
frozen tissue sections were stained 
with propidium iodide (PI) in 
VectashieldTM.  The scale bars 
represent 200 µm. [Colour in print]. 
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significantly increase the transport rate of biodegradable nanoparticles in human cervical mucus 
[23].  Based on this, and to address these two issues, we formulated PEGylated liposomes to 
facilitate the transport of oligonucleotides across cervicovaginal mucosal layer and thus enhance 
epithelial cell uptake.  The physical characteristics of these particles were presented in Wu et al 
[16].  Additionally, we fabricated alginate scaffolds to entrap the PEGylated lipoplexes in order to 
facilitate greater retention of these particles in the vaginal cavity following intravaginal 
administration.  We subsequently investigated the effect of various formulation methods and 
parameters on physical scaffold characteristics, entrapment efficiency, release kinetics, and 
efficacy.  
 
3.3.1. Scaffold characteristics 
Alginate scaffolds were fabricated using either a freeze-dried or an air-dried method (Fig. 4).  For 
the freeze-dried method, the water crystal formed during the freezing step was removed by 
sublimation giving rise to porous structure (Fig. 5A).  This was in direct contrast to the scaffold 
prepared using the air-dried method where the space which the water crystal occupied collapsed 
during the drying step.  The resultant scaffold was therefore less porous (Fig. 5B), which may not 
allow efficient entry of the vaginal fluid (which can be as low as 2mL/day in humans [24]).  
Additionally, the alginate scaffold prepared using the freeze-dried method expanded less upon 
exposure to water (22%) as compared to the air-dried method (50%) (Fig. 5C, p<0.005).  Since the 
greater expansion of the air-dried scaffold system could potentially result in vaginal discomfort 
following application, the freeze-dried fabrication method was thus employed for all our subsequent 
experiments.   
 
Figure 3 Citric acid pre-treatment 
improved the vaginal delivery efficiency 
of lipoplexes.  Some delivery of FITC-
Oligonucleotides was observed in the 
vaginal tissues following lipoplexes 
administration when the vaginal cavity 
was pre-treated with 5% citric acid for 2 
hrs.  The bottom panel shows 
magnification of the area outlined in the 
middle right image.  The oligonucleotides 
(2,000 pmol) were delivered using 
DOTAP liposomes and no fluorescein 
autofluorescence was detected in the 
control animal (treated with 5% citric acid 
only).  All images were obtained at 
twenty-four hrs post-treatment and frozen 
tissue sections were stained with 
propidium iodide (PI) in VectashieldTM.  
The scale bars represent 200 µm (top two 
panels) and 20 µm (bottom panel). 
[Colour in print]. 
 
Figure 4 Flow chart of the fabrication of 
alginate scaffolds via freeze-dried and air-
dried methods. 
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3.3.2. Entrapment efficiency, particle characterisation, and release kinetics 
We next investigated the efficiency of incorporating PEGylated liposomes into alginate scaffold 
using various alginate:lipid (w/w) ratios.  PEGylated liposomes were formulated using the 
Hydration of the Freeze-Dried Matrix (HFDM) method we previously developed, where entrapment 
efficiency of oligonucleotides was found to be over 90% [16].  The lipoplexes were then mixed 
with the alginate solution prior to the freeze-drying step (Fig. 4).  Importantly, the efficiency of the 
HFDM-formulated lipoplexes to deliver siRNA in vitro was not diminished after being subject to 
freeze drying process twice (data not shown).  The entrapment efficiency of these lipoplexes within 
the scaffold was determined by subtracting the amount of oligonucleotides removed by the CaCl2 
solution used to cross-link the scaffold device from the initial amount.  We found that the 
entrapment efficiency increased with increasing amount of alginate used, with 50% entrapment 
efficiency achieved at alginate:lipid ratios of 8:1 or 10:1 compared to 40% when formulated at 
alginate:lipid ratios of 5:1 or 6:1 (Fig. 6A, p<0.005 and p<0.05 for 8:1 and 10:1 formulations, 
respectively).  We next examined the impact of alginate on the particle size of PEGylated lipoplexes 
following lyophilisation.  PLAS systems formulated with alginate:lipid ratios of 6 and 8 were 
examined.  Following hydration and centrifugation at 5000g for 10 mins to remove still-yet-to-be 
degraded alginate scaffold, more than 80% of the siRNA still remained in the supernatant, which 
allowed us to objectively assess the particle size of the released lipoplexes.  The average particle 
size of the lipoplexes was found to be 300.68 (SD=58) nm and 368.93 (SD=53) nm for formulations 
prepared at alginate:lipid ratios of 6 and 8, respectively.  The polydispersity indexes (PI) were 
around 0.4 for both formulations.  It must be noted that the particle size observed for these alginate 
scaffold-embedded lipoplexes is considerably larger than “free” lipoplexes (<200nm) and could be 
contributed by the association of alginate on the surface of these liposome particles.  
While the pH of the vaginal tract in mice is around 6.5 [25], the release kinetics were assessed using 
with a slightly more acidic citrate buffer (pH5) to mimic the pH of human vaginal tract (pH ~4) [26, 
27].  As shown in Fig. 6B, the liposome-alginate scaffold formulated at an alginate:lipid ratio of 
10:1 exhibited a slightly slower release rate with 25% of the lipoplexes being released at 1 hr 
following incubation as opposed to 40% for formulations prepared at lower alginate:lipid ratios (5:1 
– 8:1).  This amount of lipoplex release (25%, 1 hr, w/w 10:1) was also found to increase 
significantly to 50% when the sodium content in citrate buffer was increased by 40% at the same 
pH (data not shown), suggesting that the release rate is dependent on the rate of calcium-sodium 
exchange in the alginate system.  Importantly, given that the sodium content in the vaginal fluid is 
Figure 5 Characteristics of the alginate scaffold prepared using either the freeze-dried or the 
air-dried method.  SEM image of the scaffold fabricated using the freeze-dried method (A) showed 
more porous structure compared to ones prepared using the air-dried method (B).  (C) Comparison 
of the percentage of expansion in volume when the scaffolds prepared using these two different 
methods were moisturised with water.  Bars represent the mean value (n=6-8) and error bars 
represent the corresponding SEM.  **p<0.005, compared to freeze-dried method. 
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>4 times less than the amount of sodium contained in citrate buffer used here [24] (Fig. 6B), one 
would expect that the release rate of lipoplexes to be much slower in vivo.  Indeed, when PBS 
(contained 40% less sodium than citrate buffer) was used, only 10% of the lipoplexes were released 
following 24 hrs of incubation as opposed to 60% in citrate buffer for formulation prepared at 
alginate:lipid ratio of 30:1 (data not shown). 
 
3.3.3. In vitro and in vivo efficacy 
To investigate how the presence of alginate affects the delivery efficiency of PEGylated lipoplexes, 
we evaluated cell uptake using FITC-labelled oligonucleotides.  The alginate system was 
formulated as described earlier but without cross-linking with calcium to eliminate effects of release 
kinetics on the uptake efficiency between different formulations.  We found that the cell uptake 
efficiency decreased with increasing alginate concentration in the formulation, with 50% reduction 
in cell uptake efficiency observed when alginate:lipid ratio increased from 5:1 to 10:1 (Fig. 7A).  
The reduced uptake of the lipoplexes was likely due to the negative charge of alginate on the 
surface of the particles.  It must be noted, however, that even at alginate:lipid ratio of 10:1, 
significant uptake of lipoplexes into cells was still observed (approximately 6.6 fold increase in 
average fluorescence intensity compared to untreated cells).   This indicated the association of 
liposomes with siRNA following their release from the alginate scaffold as no such uptake could be 
observed when naked FITC-labelled oligonucleotides were incorporated within the scaffold system 
(data not shown).  We next assessed the ability of these alginate scaffold systems to deliver siRNA 
by assessing the level of green fluorescence protein (GFP) knockdown in GFP-expressing HeLa 
cells using GFP-targeted siRNA.  We used an alginate:lipid ratio of 8:1 for this experiment given 
acceptable entrapment and cell uptake efficiencies achieved at this ratio (Fig. 6A and 7A).  Since 
the association of alginate with PEGylated particles could affect both their cellular uptake and 
endosomal release, it was not surprising that the gene silencing efficiency of PEGylated lipoplexes 
was lowered by about 50% when incorporated with alginate scaffold at a ratio of 8:1 (alginate:lipid) 
compared to unincorporated PEGylated lipoplexes (Fig. 7B).  It must also be noted that the level of 
GFP knockdown by siGFP is significantly lower when delivered using PEGylated lipoplexes (35 
Figure 6 Entrapment efficiency and 
release kinetics of the PEGylated lipoplex-
entrapped alginate scaffold (PLAS) 
system.  (A) The entrapment efficiencies of 
PEGylated lipoplexes within the alginate 
scaffold for samples prepared at 
alginate:lipid (A:L) ratios ranging from 5:1 
to 10:1.  Bars represent the mean value (n=3) 
and error bars represent the corresponding 
SEM. *p<0.05, **p<0.005, compared to the 
formulation prepared at an A:L ratio of 5:1.  
(B) The release of PEGylated lipoplexes 
from the scaffold systems over time in 
citrate buffer (pH 5) for formulations 
prepared at A:L ratios ranging from 5:1 to 
10:1. 
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%) compared with OligofectamineTM (58 %).  This is likely to be contributed to by PEG’s 
interference with cellular uptake and the release of siRNA from the endosomal compartment [28], 
though its presence is critical for the muco-penetrative property of these particles [23]. 
 
While the delivery efficiency of PEGylated lipoplexes in vitro diminished in the presence of 
alginate, we hypothesised that the longer retention of the scaffold in the vaginal cavity along with 
the potential of PEG to facilitate the transport of lipoplexes across the mucosal barrier would result 
in superior delivery efficiency in vivo compared to cationic lipoplexes.  Using the same 
administration technique, dose, and time point, it was found that the amount of FITC-labelled 
oligonucleotides delivered into vaginal tissues using the PLAS system (A:L 8:1) (Fig. 8) was 
significantly more than that observed with cationic lipoplexes (Fig. 3).  Indeed, following 
quantification of 5 randomly selected images from each treatment group, we showed a 6-fold 
increase in the percentage of uptake of FITC-Oligonucleotides into vaginal tissues for PLAS system 
compared with cationic lipoplexes (16.84% vs. 2.68%, Fig. 9).  We next assessed the level of target 
gene knockdown by siRNA using Lamin A/C siRNA-containing PLAS system (A:L 8:1) in mice.  
Despite the observed variability between mice within each treatment group, the knockdown of 
Lamin A/C in vaginal tissues for mice which have received the Lamin A/C siRNA treatments was 
evident compared to mice which have received the control siRNA treatments (85% knockdown, 
Fig. 10).  These results therefore demonstrated the promise of the PLAS system as an efficient 
vaginal siRNA delivery system.  
 
Figure 7 In vitro efficacy of the PEGylated lipoplex-entrapped alginate scaffold (PLAS) system.  (A) 
Cell uptake efficiency of the FITC-Oligonucleotides-entrapped PEGylated lipoplexes (LP) in the presence 
of alginate for formulations prepared at alginate:lipid (A:L) ratios ranging from 5:1 to 10:1.  Experiment 
was performed using HeLa cells at oligonucleotides concentration of 100nM and cells were examined for 
fluorescence intensity by FACS following an overnight incubation.  (B) The ability of the PEGylated 
lipoplexes to deliver siRNA at an A:L ratio of 8:1 was examined using GFP-targeted siRNA in GFP-
expressing HeLa cells.  Cells were incubated with the formulation for 48 hrs prior to analysis by FACS.  
Bars represent the mean value (n=3) and error bars represent the corresponding SEM. 
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Figure 9 Percentage of FITC-positive 
vaginal tissues following vaginal 
administration of FITC-
Oligonucleotides delivered using 
cationic lipoplexes or PEGylated 
lipoplex-entrapped alginate scaffold 
(PLAS) system. 
 
Figure 10 Knockdown of Lamin A/C in vaginal tissues 
using siLamin A/C-containing PLAS (A:L 8:1) system.  
(A) Western analysis of the lamin A/C level.  Each lane 
represents the Lamin A/C level in the vaginal tissue in 
each individual mouse.  Mice received two doses of Lamin 
A/C or control siRNA treatment (600pmole/dose) 
intravaginally and three mice were used per treatment 
group.  All mice were pre-treated with 5% citric acid 2 hrs 
prior to siRNA administration.  (B) Quantitative analysis 
of the combined LaminA and C levels between treatment 
and control groups.  **p<0.01, significantly different from 
control treatment group. 
 
Figure 8 Vaginal delivery efficiency of the PEGylated lipoplex-entrapped alginate scaffold 
(PLAS) system.  Clear uptake of FITC-Oligonucleotides into vaginal tissues was observed following 
intravaginal implantation of the FITC-Oligonucleotides-containing PLAS system (2,000 pmol, bottom 
panel).  The scaffolds were prepared at an alginate:lipid (A:L) ratio of 8:1 and three mice were used for 
the treatment group.  All mice were treated with 5% citric acid for 2 hrs prior to administration.  No 
fluorescein autofluorescence was detected in either the control mice (treated with 5% citric acid only) 
or mice treated with alginate scaffolds which do not contain lipoplexes.  All images were obtained at 24 
hrs post-treatment and frozen tissue sections were stained with propidium iodide (PI) in VectashieldTM.  
The images shown for the lipoplex/alginate hybrid system were representative of three mice.  The scale 
bars represent 200 µm. [Colour in print]. 
 
(A) 
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4. Discussion 
To date, several groups have reported varying success in delivering siRNA to the vaginal tract, from 
simple application of lipoplexes into the vaginal cavity with [3] or without [18] progesterone 
treatment, to thorough cleaning of the vaginal tract prior to siRNA administration [7].  The 
discrepancy in the administrative methods between these studies has prompted us to investigate the 
challenges of delivering siRNA to vaginal tissues under normal physiological conditions without 
progesterone treatment, which may more accurately represent the human vaginal tract [29].  This is 
because progesterone treatment cannot only arrest mice in the diestrus phase of the estrous cycle but 
is also typically associated with a thinned vaginal epithelia that may facilitate epithelial penetration, 
a morphology unlike any human estrous phase [29].  Its use has also been associated with increased 
rates of vaginal infections and decreased immune response in the vagina [30].   
 
In contrast to previous reports [3, 18], we found that conventional lipoplexes are not retained in the 
vaginal cavity following administration and are unable to reach the cervicovaginal epithelium under 
normal physiological conditions (not hormone treated, Fig. 2).  This was unsurprising as particles as 
small as 59 nm have been shown to unable to diffuse through human cervical mucus due to their 
extensive interaction with mucins fibers, despite its average pore size of 340 nm [31, 32].  Mucus 
thus presents as one of the most significant barriers to effective vaginal delivery [21].  To address 
this, groups have shown that dense coatings of low MW PEG can shield nanoparticles from 
adhesive interactions with mucus enabling these particles to diffuse more freely in the presence of 
mucin fibers [23, 33, 34].  This is critical as we found that even when the vaginal cavity was pre-
treated with citric acid, which could induce transient and reversible openings of the tight junction in 
the vaginal epithelium [19], minimal uptake of conventional lipoplexes into vaginal tissues was 
achieved suggesting that a significant amount of lipoplexes were still trapped in the mucus layer 
and were rapidly cleared (Fig. 3).  The importance of developing muco-penetrative particles was 
further demonstrated when N-9, a non-ionic detergent widely used in vaginal gels, lubricants, and 
condoms [35], failed to enhance the delivery of lipoplexes to the underlying epithelium despite its 
ability to disrupt vaginal epithelium [17, 36] (data not shown).  While it is possible that the 
liposome structure could have been destroyed in the presence of the detergent (N-9) leading to 
ineffective delivery, the ability of N-9 to dissociate hydrophobically-bundled mucin fibers could 
have also contributed to this given its ability to decrease the average mucus pore size from 200-500 
nm to 130 nm [37, 38]. 
 
It was thus hypothesised that PEGylated lipoplexes would serve as a more appropriate delivery 
vector for vaginal siRNA delivery.  However, the ability of these lipoplexes to be retained in the 
vaginal cavity following administration was a concern due to its liquid nature, a feature that is 
similar to currently available formulations [3, 6, 7, 18].  To address this, we formulated a solid 
PLAS system where PEGylated lipoplexes could be released from solid alginate scaffolds gradually 
overtime.  Importantly, unlike the poly(ethylene-co-vinylacetate) (EVAc) disc which has previously 
been used to deliver plasmid DNA in a sustained manner in the vaginal cavity [39], alginate is 
biodegradable thus presents an attracting alternative.  While the particle size of these lipoplexes 
increased significantly from 200nm to around 350nm in the presence of alginate, given that the pore 
size of cervicovaginal mucus ranges from 50-1800nm with a size of 340 +/- 70nm [38], these 
PEGylated muco-inert particles could still penetrate the mucus layer lining cervicovaginal tissues 
readily.   
 
The mechanism by which the PEGylated lipoplexes is released from the scaffold was likely through 
a combination of surface desorption, diffusion, and alginate degradation.  The reduced interaction 
between lipoplexes and alginate scaffold due to the presence of PEG likely has resulted in the initial 
burst release of our particle from the scaffold system (Fig. 6B) [40].  However, the sustained release 
nature of the PLAS system following this initial burst release indicated that that PEGylated 
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lipoplexes were entrapped within the scaffold system at least to some extent rather than merely 
being immobilized on its surface.  Given that the increased alginate concentration in the formulation 
could significantly prevent the loss of lipoplexes during the cross-linking procedure (Fig. 6A), it 
was not surprising to see that the release rate of lipoplexes decreased with increasing alginate 
concentration (Fig. 6B).  Importantly, we found that the remains of the alginate scaffolds (w/w 8) 
could still be observed in the vaginal tract at 24 hrs post intravaginal administration.  This was in 
direct contrast to the in vitro study where the scaffolds were almost completely disappeared within 
3 hrs of incubation in citrate buffer (Fig. 6B).  This discrepancy was likely due to the difference in 
sodium level in the buffer compared to the vaginal fluid [24] as well as the vast difference in the 
fluid volume present between in vitro (5 mL) and in vivo (50 μL) conditions.  Indeed, when 
OptiMemTM or PBS was used, we observed minimal degradation of these scaffold systems at 24 hrs 
post incubation (data not shown), which is consistent with many other scaffold device made of 
fibrin [41] or collagen [40]. 
 
Importantly, the released PEGylated lipoplexes from the alginate system were shown to be able to 
enter cells efficiently and resulted in target gene knockdown, though the efficiency was diminished 
with the increased level of alginate in the formulation (Fig. 7).  It must be noted that while a few 
reports have shown superior delivery of plasmid DNA or siRNA using alginate [11] or collagen 
[42] based scaffold systems compared to the one reported in this manuscript, the transfection agent 
used in those studies were non-PEGylated and the cells were also embedded directly within the 
scaffold system for tissue regeneration purposes.  A direct comparison of the delivery efficacy 
between these studies is therefore difficult.  Despite this, the observed reduction of the gene 
silencing efficiency of siRNA in the presence of alginate (Fig. 7B) was similar to that reported for 
PEG-polyethyleneimine(PEI)-alginate nanoparticles where their gene silencing efficiency was 
found to be inferior than that of parent PEG-PEI nanoparticles, though the exact degree of reduction 
was not reported [13].  The mechanism by which alginate decreases the delivery efficiency of 
PEGylated particles, but not non-PEGylated ones, is not well understood at present [13].  
Nevertheless, we showed that in the in vivo setting, the PLAS system delivered oligonucleotides 
into vaginal tissues at a much higher efficiency than cationic lipoplexes (6-fold increase, Fig. 3, 8, 
and 9).  The enhanced delivery was likely due to a combination of the improved penetration of 
PEGylated lipoplexes across the mucosal layer compared to non-PEGylated counterparts as well as 
the ability of the scaffold to remain in the vaginal cavity following administration.  The promise of 
this PLAS system to deliver nucleic acids intravaginally was further demonstrated when an 85% 
knockdown of Lamin A/C was observed following two consecutive treatments of Lamin A/C-
targeted siRNA in mice (Fig. 10).  While this is encouraging, future effort should focus on 
optimising formulation method and parameters, such as the degree of cross-linking, particle size 
[31], amount of PEGylation [33], type of alginate [10, 43], or formulation procedures [44], in order 
to improve the mucus-penetration, release kinetics and vaginal retention time of the PLAS system.  
These optimisations along with the establishment of a feasible treatment regimen will be critical in 
the future in order to achieve clinically significant therapeutic response following intravaginal 
administration and will therefore be the next set of challenges.  In particular, enhancement of the 
muco-penetrative ability of the PLAS system will be crucial for its future clinical applicability as 
the need of pre-treatment of vaginal cavity with citric acid could potential lead to increased 
susceptibility to infections.  Despite this, the simple formulation procedure described here for the 
PLAS system provided us with an attractive reservoir platform for vaginal delivery of nucleic acids.  
It avoids the use of organic solvents which are typically required for fabrication of other types of 
scaffold systems [42, 45].  Ultimately, the successful development of such system carries great 
potential in the vaginal administration of siRNA for localized diseases. 
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5. Conclusion 
With the recent identification of siRNA targets for cervical cancer (E6, E7 and Grb10) [14, 46], 
HIV infections (CCR5) [47], or HSV-2 infections (UL-29 and UL-27) [3], vaginal application of 
siRNA has great appeal and importance.  To our knowledge, this is the first report on the combined 
use of biodegradable scaffold and liposomes for mucosal delivery of siRNA.  We demonstrated for 
the first time the feasibility of entrapping PEGylated lipoplexes in a solid, negatively charged 
alginate scaffold system and we found that the delivery of nucleic acids into vaginal tissues was 
significantly enhanced compared to conventional lipoplexes following intravaginal administration.  
Using the PLAS system, a significant siRNA-mediated knockdown of the target gene was observed 
in vaginal tissues following intravaginal administration.  Overall, this novel hybrid system presents 
an innovative approach for the vaginal delivery of nucleic acids and its ease of administration and 
preparation offers vital features for rapid clinical development and patient compliance. 
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